Towards precision secondary prevention after myocardial infarction and stroke with glucagon-like peptide-1 receptor agonists - Takeaways - MDSpire

Towards precision secondary prevention after myocardial infarction and stroke with glucagon-like peptide-1 receptor agonists

  • By

  • Fariba Ahmadizar

  • Joline W J Beulens

  • January 29, 2026

  • 0 min

Share

  • 1

    Patients with Type 2 diabetes post-myocardial infarction or stroke are at high risk for recurrent cardiovascular events and mortality.

  • 2

    GLP-1 receptor agonists have shown cardiovascular benefits beyond glycemic control, reducing major adverse cardiovascular events.

  • 3

    Real-world evidence indicates low initiation rates of GLP-1RA therapy among high-risk patients after myocardial infarction or stroke.

  • 4

    Initiation of GLP-1RA therapy is associated with significantly lower risks of major adverse cardiovascular events and mortality.

  • 5

    The observed benefits of GLP-1RA therapy may be overestimated due to unmeasured confounding factors in registry data.

Original Source(s)

Towards precision secondary prevention after myocardial infarction and stroke with glucagon-like peptide-1 receptor agonists

  • by Fariba Ahmadizar, Joline W J Beulens

  • January 29, 2026

Related Content

Bubble-test for detection of a patent foramen ovale in young to middle-aged ischemic stroke patients

What RVO May Reveal About Systemic Health

TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.

Systemic immune-inflammation index predicts post-thrombectomy outcomes and reveals a mediating role in the association between neurocardiac stress and prognosis: a multicenter study